Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 17, 2024Journal of Antimicrobial Chemotherapy

DORAVIR: a French national survey of people with HIV-1 treated with an antiretroviral regimen including doravirine

View Full Paper
Ask AI
Bookmark
Share

Authors

CSCathia SouliéABAliou BaldéDFDjeneba Fofana

Discussion

Loading...

Member takes

Overview

National survey observes virological efficacy and resistance mutations in people with HIV-1, highlighting therapeutic outcomes of doravirine.

Key Points

  • Assessment of doravirine focuses on virological efficacy and treatment durability among individuals living with HIV-1 receiving daily therapy.
  • Analysis examines virological failure rates alongside the emergence of reverse transcriptase mutations under contemporary NNRTI regimens.
  • Findings highlight distinct resistance profiles of next-generation antiretroviral regimens, informing future management of virological failure.

Cite This Study

Soulié et al. (2024) studied this question.

synapsesocial.com/papers/68e64768b6db6435875d8b31https://doi.org/10.1093/jac/dkae194
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Long‑Term Effectiveness and Safety of Doravirine‑Based Antiretroviral Regimens in Virologically Suppressed People with HIV: The French Dat’AIDS Cohort2026
  2. 2Long-term effectiveness, safety, and tolerability of doravirine in antiretroviral-experienced people with HIV in real life2024 · 6 citations
  3. 3Doravirine/Islatravir: A 2-Drug Regimen for the Treatment of HIV-1 Infection2026
  4. 4The efficacy and safety of doravirine/lamivudine/tenofovir disoproxil fumarate in treatment-naïve and treatment-experienced patients with HIV2025
  5. 5Switching to doravirine-based antiretroviral therapy without genotypic resistance tests in virologically suppressed people with HIV2026